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Abstract
Background: Asthma is the most common chronic disease in children, occurring at higher frequencies and with
more severe disease in children with African ancestry.
Methods: We tested for association with haplotypes at the most replicated and significant childhood-onset asthma
locus at 17q12-q21 and asthma in European American and African American children. Following this, we used wholegenome sequencing data from 1060 African American and 100 European American individuals to identify novel variants on a high-risk African American–specific haplotype. We characterized these variants in silico using gene expression and ATAC-seq data from airway epithelial cells, functional annotations from ENCODE, and promoter capture (pc)
Hi-C maps in airway epithelial cells. Candidate causal variants were then assessed for correlation with asthma-associated phenotypes in African American children and adults.
Results: Our studies revealed nine novel African-specific common variants, enriched on a high-risk asthma haplotype, which regulated the expression of GSDMA in airway epithelial cells and were associated with features of severe
asthma. Using ENCODE annotations, ATAC-seq, and pcHi-C, we narrowed the associations to two candidate causal
variants that are associated with features of T2 low severe asthma.
Conclusions: Previously unknown genetic variation at the 17q12-21 childhood-onset asthma locus contributes to
asthma severity in individuals with African ancestries. We suggest that many other population-specific variants that
have not been discovered in GWAS contribute to the genetic risk for asthma and other common diseases.
Keywords: Asthma, Fine mapping, Integrated omics, Whole-genome sequencing, Health disparities
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Background
Genome-wide association studies (GWAS) have identified thousands of loci associated with hundreds of
common traits and diseases, providing insights into
pathogenic pathways and yielding a plethora of candidate
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causal single-nucleotide polymorphisms (SNPs) and
genes for follow-up studies. Yet the overwhelming majority of GWAS have been performed in individuals of
European or Asian ancestry with poor representation of
global diversity [1, 2]. Even if many causal variants are
shared between populations [3], some will surely differ,
and some may even be population-specific [4, 5]. The
full range of risk variants will never be discovered from
studies that are limited to European-ancestry populations. Thus, imprecise predictors of genetic risk in African-ancestry populations will arise from a variety of
mechanisms, including a relative dearth of knowledge of
African-specific risk variants.
The 17q12-q21 childhood-onset asthma locus provides
an edifying example of multi-ancestry complexities of
genetic risk. A distinguishing feature of this locus is that
it is the most statistically significant and most replicated
childhood-onset asthma locus in GWAS of Europeanancestry populations [6–8], as well as in a multi-ancestry
[9] and an African-admixed [10] asthma GWAS. However, whereas odds ratios (ORs) for childhood-onset
asthma at the most significant SNP in white British individuals was 1.40 (95% confidence interval [CI] 1.36, 1.44)
[8], ORs for pediatric asthma at the most significant SNPs
were 1.25 (CI 1.20, 1.29) in the multi-ancestry GWAS [9]
and 1.35 (CI 1.13, 1.35) in the African-admixed GWAS
[10]. In the African-admixed GWAS, the magnitude of
the effect size was inversely correlated with the proportion of African ancestry [10]. These combined data suggested that the same SNPs at the 17q12-q21 locus may
have different effects on asthma risk in individuals with
African ancestry.
A second characteristic of this locus is ancestry-specific patterns of linkage disequilibrium (LD) [11]. Extensive LD in European-ancestry populations results in a
150-kilobase (kb) block of tightly linked SNPs. Therefore, although the lead SNP in European-ancestry GWAS
often differs between studies, it always resides on the
same extended haplotype (reviewed in ref. [11]). In contrast, considerably less LD occurs at this locus on African-ancestry chromosomes and, as a result, SNPs that
tag causal variant(s) in European-ancestry populations
may not tag the same causal variants in African-ancestry
population, possibly accounting for the smaller effect
sizes observed at GWAS loci in these populations.
A final feature of the 17q12-q21 locus is that SNPs
spanning the 150-kb LD block in European-ancestry populations are expression quantitative trait loci
(eQTLs) for two genes, ORM1-like 3 (ORMDL3) and
gasdermin B (GSDMB), in blood cells, lung tissue, and/
or airway epithelial cells [6, 12–16]. The reduced LD on
African-ancestry chromosomes and the eQTL effects
have recently been leveraged for fine mapping, revealing
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that the association with childhood-onset asthma at this
locus is due to genetic variation influencing the expression of GSDMB [17, 18], particularly in airway epithelial cells [17]. The childhood-onset asthma–associated
alleles at a missense SNP in GSDMB, rs2305480-G, had
an estimated OR for childhood-onset asthma of 1.17 (CI
1.05, 1.30) in a meta-analysis of 3904 African American
subjects [17]. Using rs2305480 and four other tag SNPs
across the 150-kb core region, alleles at two SNPs associated with risk for childhood-onset asthma in Europeanancestry children (rs12936231, rs4065275) had estimated
ORs <1 in African American children [17], suggesting
that differences in the local haplotype structure may be
contributing to the 17q12-q21 disease liability for childhood-onset asthma in African-ancestry populations.
Based on these earlier results, we hypothesized that
additional variation on African-ancestry chromosomes
within the core region of the 17q12-q21 locus modifies
risk for childhood-onset asthma. In this study, we explore
this hypothesis by first performing haplotype-based
analyses in the same 868 African American children
as in our earlier study [17] and then use whole-genome
sequences from 100 European American and 1060 African American individuals to characterize the haplotype
structure at this locus at single-nucleotide resolution.
Ultimately, we defined a 26.3-kb critical region in the
17q12-q21 core region of a high-risk haplotype that
included nine African-specific variants. These variants
were eQTLs in airway epithelial cells only for gasdermin
A (GSDMA), overlapped with Encyclopedia of DNA Elements (ENCODE) [19] enhancer annotations in multiple
cell types and with open chromatin in airway epithelial
cell lines, and physically interacted with the promoter
of GSDMA by promoter capture (pc)Hi-C in primary
airway epithelial cells [20]. The novel variants were also
associated with measures of severity in African American
children and adults. We suggest that additional examples
of non-European-ancestry–specific variants may underlie ancestry-specific differences in disease liability and
effect size estimates at other asthma loci as well as at loci
associated with other common diseases. An overview of
our study design is shown in Additional file 1: Fig. S1.

Methods
Study cohorts

The individual cohorts used in these studies are described
in Additional file 1: Supplementary Methods.
17q12‑q21 Haplotype Analysis in the Children’s
Respiratory and Environmental Workgroup (CREW) Cohort
[21]

Most of the participants in CREW were not genotyped
with genome-wide SNPs. Therefore, we genotyped nine
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tag SNPs across the extended 17q12-q21 region using
TaqMan assays in a previous study [17]. These SNPs were
selected to capture the LD pattern in African-ancestry
populations and to represent variants that were either
(i) the lead SNP in a previous asthma GWAS, or (ii) a
known eQTL for any of the genes across the extended
locus, as presented in Stein et al. [11]. Based on our previous results [17], we selected the five SNPs that tagged
the core region for these studies. We performed haplotype analysis in the 1647 parent-reported Non-Hispanic
White (NHW) and 868 parent-reported Non-Hispanic
Black (NHB) participants who were followed to at least
age 6 years and were genotyped for SNPs at the 17q12q21 locus as part of our earlier study [17]. Because this
locus is associated with wheezing illnesses in early life
[12, 22–24] and asthma by age 5 years [25], we used
healthcare provider–diagnosed asthma by age 6 years
to define cases and never-diagnosed asthma by age 6 or
by the last age at which the participant was studied after
age 6 to define the controls. Of the 1647 NHW subjects,
300 were asthma cases and 1347 were non-asthmatic
controls; among the 868 NHB subjects, 318 were asthma
cases and 550 were non-asthmatic controls. Additional
details on these cohorts and genotyping methods are
provided in our earlier report [17] and in Additional
file 1: Supplementary Methods.
Because we did not see evidence of association
between asthma and SNPs in the regions proximal and
distal to the core region in NHB subjects in our previous study [17], we included here the five SNPs that were
genotyped in the 17q12-q21 core region to estimate haplotypes separately in the NHW and NHB individuals. We
used haplo.em, as described in Schaid et al. [26], and the
default settings in the haplo.stats package for genotype
data. The median estimated haplotype posterior probability for the included individuals was 1.0 (interquartile
range 0.99 to 1.0; minimum 0.45). We tested the additive effects of each haplotype on asthma risk relative to

the European-protective 5-SNP haplotype (rs12936231G_rs2305480-A_rs7216389-C_rs4065275-A_rs8076131G) separately in NHW and NHB subjects using logistic
regression to generate ORs and 95% CIs, as implemented
in haplo.glm [27]. This method uses the posterior probabilities of the haplotype assignments iteratively to weight
the regression coefficients. Only haplotypes with frequency ≥0.05 were included, resulting in one test (two
haplotypes) in the European American sample and three
tests (four haplotypes) in the African American sample.
Sex and recruitment city were included as covariates in
each model. Because genome-wide genotypes were not
available for all the subjects in this study, we could not
correct for genetic ancestry in this analysis.
Whole‑genome sequence curation and phasing

We included publicly available whole-genome sequence
data from the EVE [28] and Consortium on Asthma in
African-ancestry Populations in the Americas (CAAPA)
[29, 30] studies, as well as newly generated wholegenome sequences [31] in the Asthma Phenotypes in
the Inner City (APIC) [32] and Urban Environment and
Childhood Asthma (URECA) [33] cohorts. These cohorts
are further described in Additional file 1: Supplementary
Methods.
We first pruned the files to include African American individuals in EVE (n=90), CAAPA (n=320), APIC
(n=321), and URECA (n=329), and European American
individuals in EVE (n=100). African American or European American ancestries were determined by ancestry
principal component (PC) analysis in each cohort. All
EVE and APIC subjects had doctor-diagnosed asthma;
CAAPA included 168 subjects with doctor-diagnosed
asthma, and URECA included 176 subjects with doctor-diagnosed asthma. These datasets are described in
Table 1 and in Additional file 1: Supplementary Methods. We used the Michigan Imputation Server [34] to
phase all variants on chromosome 17, separately in the

Table 1 Whole-genome sequence datasets
Study

Race/ethnicity

Sample sizes

dbGaP accession number

Total sample

Asthma cases

Cases homozygous for a
5-SNP haplotype

Reference

URECA

African American

329

176

36

phs002921.v1.p1

[33]

APIC

African American

321

321

87

phs002921.v1.p1

[32]

CAAPA

African American

320

168

40

phs001123.v2.p1

[30]

EVE

African American

90

90

14

phs001156.v2.pa

[28]

EVE

European American

100

100

44

phs001156.v2.p1

[28]

URECA Urban Environment and Childhood Asthma, APIC Asthma Phenotypes in Inner-City Children, CAAPA Consortium on Asthma among African-Ancestry
Populations in the Americas
See “Methods” for descriptions of each cohort
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European American and African American sequences,
using the Haplotype Reference Consortium4 (r1.1 2016)
as the reference panel. Standard quality control checks
were used [34], including removal of duplicated sites,
non-SNP variants, monomorphic sites, invalid alleles,
and SNPs with call rates less than 90%.
Visualizing haplotypes

To visualize haplotypes, we used ChromoPainter [35], a
tool used for defining haplotypes in sequence data. For
this step, we used phased chromosome 17 sequences
from all individuals with whole-genome sequences. We
then selected the individuals who were homozygous
for the 5 SNPs that defined the core region haplotype
and tagged the European risk and protective haplotypes
identified in the haplotype studies described above and
in Fig. 1. We focused on homozygous individuals to
maximize the accuracy of the phasing. ChromoPainter
requires two file types: a phased genotype file and
a genetic map designating recombination distances
between SNPs. For the first, we converted the phased .vcf
genotypes files for all chromosome 17 variants into the
.phase format. For “painting” the sequences, we used the
1000Genomes recombination map [36] for the European
American chromosomes and an African American–specific map for the African American chromosomes [37].
ChromoPainter was run separately for each population
across chromosome 17.
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Using these two files, ChromoPainter “paints” each
phased chromosome by comparing it to all other phased
chromosomes in the sample. For each chromosome at
each SNP, the expected probability that an index chromosome has been copied from each of the other chromosomes is determined using a Hidden Markov Model.
ChromoPainter then outputs a matrix for each chromosome with the number of rows equal to the number of
SNPs and the number of columns equal to the number of
phased chromosomes. Each cell within this matrix contains the probability that the column’s chromosome was
copied by the index chromosome at that SNP based on
the sequence similarity of the two chromosomes and the
rate of recombination between the current and previous
SNP (Additional file 1: Fig. S2).
Chromosomes corresponding to the highest posterior probability for each SNP across the chromosome
were selected, and we then assigned haplotypes (different colors) for each row of phased SNPs based on
the 5-SNP haplotype with the highest probability (see
Fig. 2). Each horizontal line represents a single chromosome, with coloration based on the highest-probability
donor haplotype at each locus on the chromosome.
Chromosomes change color as the highest-probability
donor haplotype changes according to the maximum
posterior probability at each base pair. The median of
the maximum posterior probabilities across all base
pairs (not specifically at haplotype switches) for each
chromosome varied from 0.122 to 1.0 (median =

Fig. 1 Common haplotypes at the 17q12-q21 locus. A Ten genes and their relative locations at the extended locus (chr17:37815888-38143768;
build hg19). Genes at the core, proximal, and distal regions are color coded (modified from Stein et al. [11] and Ober et al. [17]). The five variants
defining the core region haplotypes and their locations relative to each gene are shown. B Results of logistic regression analysis for haplotypes
with frequencies ≥0.05; haplotype 1 is the reference haplotype. C Allelic composition of the five variants on four haplotypes. Yellow background
corresponds to alleles on the non-risk haplotype (haplotype 1) and red background corresponds to alleles on the risk haplotype (haplotype 2 in
European-ancestry populations). The purple star denotes the high-risk haplotype in African Americans. D Haplotype frequencies
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Fig. 2 17q12-q21 haplotypes in whole-genome sequences from
individuals with asthma and homozygous for the 5-SNP haplotype. A
Bar graph of haplotypes present in 44 Europeans (88 chromosomes)
and 177 African Americans (354 chromosomes). The allelic
composition and color code of each 5-SNP haplotype are shown
under the bars. The purple star designates the African American
high-risk haplotype 4. B ChromoPainter display of the haplotypes
(88 chromosomes) in European Americans. C ChromoPainter
display of 89 randomly selected chromosomes from the 354
chromosomes in African Americans. All chromosomes are shown
in Additional file 1: Fig. S3. The LD plots include 17 SNPs previously
associated with asthma in GWAS or with expression of genes at this
extended locus, as previously described [11], are shown below the
ChromoPainter displays. LD data are from 1000 Genomes (CEU and
ASW, respectively); r2 values are shown in each diamond. The darker
the diamond, the more LD; black diamonds are r2 = 1.0

0.883) in African Americans and 0.246 to 1.0 (median
= 0.824) in European Americans. This process was
repeated for each chromosome in our sample (2n=88
European American and 354 African American chromosomes from individuals homozygous for the 5-SNP
haplotype). After running ChromoPainter for chromosome 17, we focused on the 17q12-q21 region corresponding to chr17:39674647-39972395 (hg38), which
included the proximal, core, and distal regions, as
defined by Stein et al. [11]. LD plots of selected SNPs
at this locus were generated using Haploview [38] with
data from 1000 Genomes CEU and ASW populations
to represent European American and African American
populations, respectively.
Identifying novel variants on the high‑risk haplotype

The ChromoPainter analysis allowed us to delineate a
critical region that was shared among individuals with
the high-risk 5-SNP haplotype. Variants in the critical
region that were unique to the high-risk haplotype in
the African American sequences were selected by first
creating consensus sequences of the critical region in
individuals who were homozygous for one of the six
haplotypes (see Additional file 1: Supplementary Methods for additional details).
The African American–specific high-risk consensus
sequence was compared to each of the other five consensus sequences to identify SNPs that occurred only
on the African American–specific high-risk haplotype.
Candidate causal variants were identified at base pair
positions at which the allele on the African American
high-risk consensus haplotype always differed from the
allele present on the other five consensus haplotypes
among the 5-SNP haplotype homozygous individuals.
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eQTL mapping of African‑specific variants on the high‑risk
haplotype

Testing associations between African‑specific variants
and clinical phenotypes

eQTLs from RNA-seq data collected from upper airway (nasal) cells collected at age 11 were available for
189 African American children in the URECA cohort
[39]. See Additional file 1: Supplementary Methods
for a description of the cohort. For eQTL studies, we
included all SNPs within the 26.3-kb critical region
with minor allele frequencies ≥0.05 and used an additive effects linear model, including sex, recruitment
site, sequencing batch, epithelial cell proportion,
ancestry PC1-3, and 11 latent factors as covariates, as
implemented in Matrix eQTL [40] for a region-wide
analysis. Latent factors were included to adjust for
unwanted variation [41]. We included all African-specific variants in the 26.3-kb critical region and tested
for genotype effects of each variant on the expression
of all genes whose TSS were within ±500 kb (n=27
genes). We used an FDR threshold of ≤0.10 to control the false-positive rate. As local references, we also
performed post hoc analyses of eQTLs for the asthmaassociated rs2305480 SNP, a known eQTL for GSDMB,
and for SNPs across the GSDMA gene that were previously reported eQTLs for GSDMA.
To replicate our findings, we performed eQTL studies using nasal epithelial cell gene expression from
RNA-seq data and genotypes (MEGA array; Illumina) for 534 participants in CAAPA2 (unpublished)
(see Additional file 1: Supplementary Methods for a
description of the CAAPA cohort). Genotypes for one
of the African-specific variants (rs28623237) on the
high-risk haplotype 4 were available for these individuals. We tested for association between rs28623237
genotype and GSDMA expression (cpm) using a linear
model that included age, sex, recruitment site, RIN,
GC content, library batch, and the first two ancestry
PCs as covariates.

To examine the phenotypic effects of the African-specific variants, we used harmonized phenotype data in
the APIC and URECA cohorts for seven asthma-associated quantitative traits in African American individuals:
pre-bronchodilator % predicted FEV1 (n=607), FEV1/
FVC (n=596), FeNO (n=423), bronchodilator response
(n=589), total serum IgE (n=604), blood eosinophil
count (n=606), and blood neutrophil count (n=606).
These cohorts are described in Additional file 1: Supplementary Methods and Table S1. We used a linear mixed
model [43] to test for additive effects of the African-specific variant, including age, sex, asthma status, and ancestry PC1-3 as covariates and a kinship matrix as a random
effect to adjust for relatedness. To adjust for seven tests,
we tested the joint null hypothesis that none of the associations are significant [44]. This test is an alternative
to the more commonly used, but highly conservative,
Bonferroni adjustment. We adjusted the null distribution to account for the correlations between the seven
phenotypes.
We also tested for associations with asthma severity in 63 African American adults who participated in
the Chicago Asthma Genetics (CAG) study [45, 46] (see
Additional file 1: Supplementary Methods). Adult asthmatics were assigned as mild (n=19), moderate (n=18),
or severe (n=26) using STEP classifications [47], which
are based on both steroid use and lung function measures. Because whole-genome sequences, and therefore
genotypes for the African-specific SNPs, were not available for these individuals, we imputed the 5-SNP haplotype from phased genotype data (Michigan Imputation
Server [34]), and then tested for associations between
of the high-risk haplotype 4 (G-G-T-A-A) frequencies
and STEP classification using ordinal logistic regression,
including age, sex, current smoking status, and ancestry
PC1-3 as covariates. Association between asthma severity and the combined effects of rs2305480 genotype and
carriage of the high-risk haplotype 4 was tested using
ordinal logistic regression, including the same covariates
as above.

Annotating variants for regulatory function

Annotation of regulatory elements in the region containing the variants specific to the African American
high-risk haplotype was conducted using publicly
available data for regulatory regions in ENCODE [19].
We specifically examined Chromatin Immunoprecipitation-seq data for H3K27ac, a marker of active
enhancers, and DNase clusters, marks of open chromatin. Finally, to identify putative enhancers that overlap with the African-specific variants, we used publicly
available pcHi-C data in primary bronchial epithelial
cells (GSE 152549) [20]. We considered only Hi-C
loops with CHiCAGO scores ≥5 [42].

Results
17q12‑q21 haplotype associations with asthma
in European American and African American individuals

We first examined associations between the common haplotypes (frequency ≥0.05) and asthma in the
same parent-reported NHW and NHB subjects in the
Children’s Respiratory and Environment Workgroup
(CREW) cohorts included in our previous study [17].
Haplotypes were assigned based on five SNPs that
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tagged the core region of the 17q12-q21 locus. The SNPs
included the missense SNP, rs2305480, in GSDMB, previously reported to be the lead SNP in these subjects
[17] and in near perfect LD with a GSDMB splice variant, rs11078928, in both European-ancestry and African-ancestry populations [18]. The two common 5-SNP
haplotypes in these samples, including the non-risk (haplotype 1) and risk (haplotype 2) haplotypes, accounted
for 92% of haplotypes in NHW individuals and 57% of
the haplotypes in the NHB individuals, with the same
directions of effect (Fig. 1). Two other haplotypes were
common in the NHB (frequencies 0.17 and 0.14 for haplotypes 3 and 4, respectively) but absent in the NHW
(Fig. 1). An additional 13 haplotypes in the NHW and
11 in the NHB were present at frequencies less than 0.05
(Additional file 1: Table S2).
Consistent with our earlier study of individual SNPs
[17], the haplotype carrying the rs2305480-G allele (haplotype 2) was associated with asthma in the NHW individuals (OR = 1.35 [CI 95% 1.11, 1.65]; p = 0.0025). In
the NHB individuals, a different haplotype also carrying
the rs2305480-G allele (haplotype 4) was most strongly
associated with asthma (OR = 1.67 [CI 95% 1.10, 2.55];
p = 0.017), whereas two other haplotypes carrying the
rs2305480-G allele (haplotypes 2 and 3) had estimated
ORs greater than 1.0 but were not statistically significant
in this sample. These results suggested that haplotype 4
carries additional variation that increases risk for asthma
in NHB individuals.
To identify variants on haplotype 4 that may be contributing to asthma risk, we first characterized the
variation at the 17q12-q21 locus using whole-genome
sequences from four datasets including either asthma
cases only (APIC and EVE) or both asthma cases and
controls (URECA and CAAPA) (Table 1). To maximize
phasing accuracy, we first focused on sequences from
asthma cases who were homozygous for the 5 common
haplotype-defining SNPs (44 European Americans and
177 African Americans). Only haplotypes 1 and 2 were
observed in the homozygous sequences of the European
American asthma cases (Fig. 2A). However, in the African American asthma cases who were homozygous for
the 5 haplotype-defining SNPs, the four common haplotypes (haplotypes 1, 2, 3, 4) and two others (haplotypes 5
and 6) were observed. Haplotypes 5 and 6 both carried
the asthma-associated rs2305480-G allele and differed
from the African American high-risk haplotype 4 by one
or two of the other haplotype-defining SNPs, respectively
(Fig. 2A).
To gain an initial overview of the sequence structure
across the extended 17q12-q21 locus, we visualized haplotypes extending beyond the core region to include the
proximal and distal regions [11] in each population using
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ChromoPainter [35] (see “Methods”). Nearly all haplotype “switching,” which represents historical recombination events, in the 88 European American sequences
were at the boundaries of the core region or within the
proximal and distal regions (Fig. 2B), consistent with LD
patterns in a European-ancestry reference population
(CEU). These sequences revealed greater diversity and
more historical recombination in African Americans,
including numerous switches within the core region,
also consistent with LD patterns in an African American
reference population (ASW) (Fig. 2C, Additional file 1:
Fig. S3). Haplotype frequencies in each whole-genome
sequence dataset are shown in Additional file 1: Table S3.
Defining a critical region and African‑specific risk variants
on haplotype 4

Because variants in the proximal and distal regions were
not associated with asthma in African Americans in our
previous study [17] and because of the observed haplotype structures and LD patterns in African Americans
(Fig. 2C), we focused on the sequences in asthma cases
homozygous for the high-risk haplotype 4 (defined by 5
SNPs) to first identify the chromosomal region(s) shared
by all haplotype 4 homozygotes (2N=36). Examining
the ChromoPainter displays revealed a 23.9-kb region
that was shared by haplotype 4 sequences and bounded
by at least two recombination events on either side, providing more confidence in the boundaries (Additional
file 1: Fig. S4). We then extended the region 1.2 kb (5%)
on either side to capture any additional variants that
may be excluded based on the small number of observed
recombination events. Ultimately, we examined a 26.3-kb
region that extended from intron 6 in GSDMB to 6.1 kb
upstream of the ORMDL3 transcription start site (TSS).
We refer to this 26.3-kb segment as the “critical region.”
To identify variants that were present in the critical region of haplotype 4 but not on any of the other
homozygous haplotypes, we defined consensus
sequences of this region for the European American haplotypes 1 and 2 and the African American haplotypes 1
through 4 (see “Methods”). We then conducted pairwise
comparisons between sequence variants in the high-risk
haplotype 4 critical region and each of the five other
haplotypes. Among the 58 variant sites in the critical
region, nine were specific to the haplotype 4 consensus
sequence, occurring at frequencies between 0.75 and 0.97
in African Americans who were homozygous for haplotype 4 (Table 2). We then expanded the sample to include
all sequences from cases and controls and not just those
homozygous for the 5-SNP haplotypes. The nine variants were absent in 187 European American sequences,
were highly enriched in 386 African American haplotype
4 sequences (frequencies between 0.495 and 0.756), and

T->C

rs73985230

chr17:39929476

chr17:39927234

chr17:39927157

chr17:39925400

chr17:39924694

chr17:39921437

chr17:39920081

chr17:39915395

chr17:39908449

Position (hg38)

Intergenic

ORMDL3 intron 1

ORMDL3 intron 1

ORMDL3 intron 1

ORMDL3 intron 3

ORMDL3 3’UTR

Intergenic

GSDMB intron 2

GSDMB intron 6

Location

0

0

0

0

0

0

0

0

0

EA_Hap1
(2n=69)

0

0

0

0

0

0

0

0

0

EA_Hap2
(2n=118)

0.019

0.019

0.019

0.019

0.033

0.024

0.024

0.066

0.024

AA_Hap1
(2n=212)

0.039

0.039

0.039

0.039

0.062

0.038

0.037

0.094

0.039

AA_Hap2
(2n=891)

0.027

0.029

0.029

0.029

0.037

0.032

0.029

0.270

0.042

AA_Hap3
(2n=408)

0.50

0.53

0.53

0.53

0.76

0.52

0.50

0.79

0.53

AA_Hap4
(2n=386)

0.75

0.78

0.78

0.78

0.94

0.78

0.78

0.97

0.78

AA_Hap4
Asthmatic,
Homozygotes
(2n=36)

2n number of chromosomes, EA European American, AA African American

The asthmatics who were homozygous for the high-risk haplotype 4 are shown in the last column. Only haplotypes included in the ChromoPainter analyses (Fig. 1) are shown. Locations are based on GENCODE (V36)
gene track data

A->T

A->T

rs113282230

rs113571956

T->C

G->A

rs28623237

rs73985229

A->G

G->A

rs73985226

rs73985227

G->A

T->C

rs150276395

rs8065520

Variant

rsID

Table 2 Location and frequencies of the nine novel African-specific SNPs in the full sample
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Table 3 cis-eQTL mapping results for the nine novel variants
SNP-effect allele

Position (hg38)

Gene

t-statistic

Beta

P-value

FDR

rs150276395-G

chr17:39908449

GSDMA

2.59

0.66

0.0100

0.320

rs8065520-T

chr17:39915395

GSDMA

3.40

0.72

0.00084

0.056

rs73985226-A

chr17:39920081

GSDMA

3.22

0.83

0.0016

0.079

rs73985227-A

chr17:39921437

GSDMA

3.51

0.89

0.00059

0.055

rs28623237-C

chr17:39924694

GSDMA

3.45

0.74

0.00072

0.056

rs73985229-A

chr17:39925400

GSDMA

3.35

0.86

0.0010

0.057

rs113282230-T

chr17:39927157

GSDMA

3.35

0.86

0.0010

0.057

rs113571956-T

chr17:39927234

GSDMA

3.35

0.86

0.0010

0.057

rs73985230-C

chr17:39929476

GSDMA

3.06

0.79

0.0026

0.110

Each variant was tested for association with expression of all genes whose transcription start site is ±500 kb away and detected as expressed in airway epithelial cells
from 189 African American children in the URECA cohort
Results with uncorrected p-values <0.05 are shown. All results are shown in Additional file 2. The t-statistic from Matrix eQTL is shown

present in lower frequency on the other 1511 African
American haplotypes (frequencies between 0.019 and
0.267) (Table 2). These frequency distributions are similar to those observed in worldwide populations (Additional file 1: Table S4). These data suggested that one or
more of these nine variants contribute to asthma risk in
African Americans.
Functionally characterizing the African American–specific
variants on haplotype 4

The nine African-specific variants that were enriched
on haplotype 4 spanned from intron 6 of GSDMB to an
intergenic region between ORMDL3 and LRRC3C. We
hypothesized that these variants modulate asthma risk
by impacting the expression of cis genes. To test this
hypothesis, we extracted processed RNA-seq data [39]
for the 27 genes whose TSS were within 500 kb of each
of the nine variants and detected as expressed in upper
airway (nasal) epithelial cells from 189 African American
URECA children. Ancestry principal components (PCs)
1 and 2 for URECA children are shown in Additional
file 1: Fig. S5. We then performed eQTL analyses of these
genes and the nine African-specific variants. At a nominal (uncorrected) p-value <0.05, all nine novel variants
were cis-eQTLs for only one of the 27 genes, gasdermin
A (GSDMA). At a false discovery rate (FDR) of ≤0.10,
seven of the nine variants remained significant (p ≤
2.5×10−3; Table 3). The results for all analyses are shown
in Additional file 2. The alleles on high-risk haplotype 4
were associated with increased expression of GSDMA
(e.g., rs113282230-T p = 1.02×10−3, b = 0.086; Fig. 3A).
This eQTL effect on GSDMA expression was replicated
in nasal epithelial cell transcripts from 534 individuals of
African ancestry in the CAAPA2 cohort (rs28623237-G p
= 8.65×10−5, b = 0.116; Additional file 1: Fig. S6).

Although SNPs within GSDMA at the distal end of
the locus were more significant eQTLs for GSDMA in
the airway epithelial cells (Additional file 1: Table S5),
the LD between the six most significant African-specific
SNPs in the 17q12-q21 core region and the eQTL SNPs
in the GSDMA gene was small (LD r2 ≤ 0.28; Additional file 1: Fig. S7). Consistent with this observation,
the eQTL effect of rs113282230-T was only modestly
reduced when we included eQTL tag SNPs from each
LD block in GSDMA as a covariate in the eQTL model
for rs113282230 (p = 2.44×10−3, b = 0.744 conditioned
on rs3859129 and p=4.69×10−3, b = 0.708 conditioned
on rs4795406; see Additional file 1: Fig. S8). These conditional analyses indicate that the observed eQTL effects of
the novel 17q12-q21 SNPs are independent of the eQTL
SNPs in the GSDMA gene.
The novel variants with eQTL effects are enriched on
haplotypes that also carry the main risk allele, rs2305480G (Table 2), which is an eQTL for GSDMB [17]. To
determine whether the effects of the novel variants on
GSDMA expression were independent of the effects of
rs2305480 on GSDMB expression and that each were
specific eQTLs for different members of the gasdermin
gene family, we performed eQTL studies with rs2305480
on GSDMA expression and with rs113282230 (as a surrogate for the nine novel variants) on GSDMB expression in
the airway epithelial cells from URECA African American children (Additional file 1: Fig. S9). These results
indicated that rs2305480 is an eQTL for GSDMB but not
for GSDMA and rs113282230 is an eQTL for GSDMA
but not GSDMB, consistent with the LD pattern between
rs113282230 and other common variants in the 17q12q21 core region (r2 < 0.11; Additional file 1: Fig. S10).
Because of the strong LD between the nine novel variants, it was not possible to statistically determine which
variants impart functional effects on gene regulation at
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Fig. 3 Functional characteristics of the African-specific novel variants on the high-risk asthma haplotype. A rs113282230, as a representative of the
novel variants, is an eQTL for GSDMA but no other genes in upper airway epithelial cells (see Table 3 for results with all nine variants and Additional
file 2 for results with all genes). BUpper panel: Chromosomal region from the 26.3-kb critical region (thick black bar) to the GSDMA gene on
chromosome 17q12-q21. Vertical lines at the top show the locations of all variants in the critical region. The location of the four genes in the region,
showing pcHi-C interactions (red arc) from a region in intron 1 of ORMDL3 to GSDMA. H3K27ac peaks (read counts; light blue tracks) in primary
normal human epidermal keratinocytes (NHEK) (ENCODE) are shown in a region overlapping with the pcHi-C capture. Lower panel: Close-up of the
26.3-kb critical region. The nine African-specific variants enriched on haplotype 4 and eQTLs for GSDMA are shown in red. The same HEK27ac peaks
as in upper panel, in addition to tracks of DNase clusters across all ENCODE cell lines, are shown. The darker the tracks the denser the DNase cluster.
Two of the nine variants, rs113282230 and rs113571956, overlap with the marks of an active enhancer (H3K27ac), open chromatin (DNAse), and a
putative enhancer (pcHi-C). See Fig. 4 and Additional file 1: Table S7 for additional annotations in airway epithelial cells and Additional file 1: Fig. S13
and Table S8 for additional annotations in immune cells

this locus. Therefore, we examined an active enhancer
mark (H3K27ac) and areas of open chromatin assessed
by DNAse in multiple cell lines from ENCODE [19] and
by ATAC-seq in two airway epithelial cells lines (human
bronchial epithelial cells, 16HBE, and small airway epithelial cells, SAEC). Two of the GSDMA eQTL variants,
rs113282230 and rs113571956, overlapped with active
enhancer marks, DNAse clusters in multiple cell types,
and ATAC-seq peaks in airway epithelial cells (Figs. 3B
and 4). DNase hypersensitivity sites of open chromatin
in all ENCODE cells and in immune cells are shown in
Additional file 1: Table S6 and Fig. S11, respectively. Next,
we extracted published data on promoter capture Hi-C
(pcHi-C) in lower airway (bronchial) epithelial cells [20]
and examined interactions with the region containing the
novel variants. Two interactions were observed between
the promoter of GSDMA and the genomic region characterized by marks of active enhancers and open chromatin, which included rs113282230 and rs113571956
(Capture HiC Analysis of Genomic Organization [CHiCAGO] scores = 6.01 and 5.07 (Fig. 3B). Additional
interactions and open chromatin marks are shown in
Fig. 4 and Additional file 1: Table S7). These data suggests that rs113282230 and rs113571956 reside in an
enhancer region that regulates the expression of GSDMA

via chromatin looping and direct interaction with its promoter and provides a mechanistic explanation for how
two novel variants in an intron of ORMDL3 regulate the
expression of GSDMA, 33.5–54.5 kb away.
To evaluate functional evidence for the 9 variants
in immune cells, we used published eQTL data in the
eQTL browser (https://fivex.sph.umich.edu/variant/eqtl/
17_39927157?g roup_by=symbol&n_labels=5&study%
5B% 5 D= S chmi e del_ 2 018& t ss_ d ista n ce= 5 0000  0 &y_
field=log_pvalue) and pcHi-C data in the Open Target browser (https://genetics.opentargets.org/variant/
17_39927157_A_T). The three most significant eQTLs
in immune cells were with increased expression of long
non-coding RNAs AC08112.1 and AC090884.2 in naïve
Tregs (p=0.0038) and Th1-17 memory cells (p=0.0043),
respectively, and with decreased expression of RARA in
Th1-17 memory cells (p=0.010) (Additional file 1: Fig.
S12). None of the promoters of these eGenes interacted
with regions that overlapped with the novel variants in
pcHi-C data in immune cells (Additional file 1: Fig. S13
and Table S8). Thus, these combined data do not support
a role for the novel variants regulating the expression of
genes in immune cells.
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Fig. 4 pcHi-C loops and ATAC-seq peaks at 17q12-q21 locus from IKZF3 to GSDMA. The region harboring the 9 novel variants is shown in yellow
and the location of the variants are show as vertical lines under the genes. The two candidate variants are indicated by an orange arrow. H3K27ac
marks in NHEK (skin) cells from ENCODE are shown as blue tracks (also see Fig. 3B and Additional file 1: Fig. S11). ATAC-seq tracks of open chromatin
for two airway epithelial cell lines (16HBE and SAEC) are shown in green. All pcHi-C interactions within this view in airway epithelial cells are shown.
Two interactions between GSDMA with three of the nine variants (±1kb) were observed (shown as red loops). Two of those variants (orange arrow)
were also eQTLs for GSDMA. All genes showing pcHi-C interactions with the 9 variants (±1kb) are shown in Additional file 1: Table S7

Associations between African‑specific variants and clinical
correlates of asthma

The results described above highlighted two novel African-specific variants, rs113282230 and rs113571956,
that were enriched on the asthma high-risk haplotype,
were eQTLs for GSDMA, and mapped within a putative enhancer element that physically interacted with
the promoter of GSDMA. These SNPs were in perfect
LD in our sample (r2 = 1; Additional file 1: Fig. S7), so
we arbitrarily selected one (rs113282230) for further
analyses with clinical measures. We first examined seven
asthma-associated quantitative traits that were available
for the African American children in both the APIC and
URECA cohorts (n=607). Descriptions of these cohorts
are shown in Additional file 1: Table S1; ancestry PCs 1–2
in each population are shown in Additional file 1: Fig. S5.
These seven traits represented the lung function (prebronchodilator %predicted forced expiratory capacity
at 1 s [FEV1], n=607; FEV1/forced vital capacity [FVC],
n=601; bronchodilator response, n=588), airway inflammation (fractional exhaled nitric oxide [FeNO], n=423),
allergic (total immunoglobulin E [IgE], n=604), and
immune cell (blood eosinophil count and blood neutrophil count, n=606) components of asthma.
Three phenotypes were associated with rs113282230
at nominal significance (p<0.05): %predicted FEV1 (p
= 9.06×10−3), blood neutrophil count (p = 0.016), and
total IgE (p = 0.042) (Fig. 5A). The asthma risk alleles
were associated with lower values of FEV1, total IgE,
and neutrophil counts. None of the tests were significant after adjusting for seven tests using the conservative

Bonferroni correction (p <0.007). However, using the correlation between z-scores of the seven traits, we calculated the probability of observing at least three tests with
p<0.05 by chance and rejected the global null hypothesis
that none of the traits are associated with rs113282230
(p = 0.0089) [44]. The results for all nine variants and all
seven traits are shown in Additional file 1: Table S9.
Taken together with the chromatin annotations and the
results of the haplotype studies in the CREW cohorts,
these clinical data suggested that the rs113282230T allele increases the risk of asthma in carriers of the
rs2305480-G allele. To examine this more directly, we
tested the additive effects of the rs113282230-T allele in
rs2305480-AA (low risk) and rs2305480-GG (high-risk)
homozygotes (coded as 0 or 1). If the rs113282230-T
allele had no effect on risk, then rs2305480-GG homozygotes should have similar risk regardless of the number
of rs113282230-T alleles. In contrast to this null expectation, we observed an increasing prevalence of asthma
with increasing numbers of rs113282230-T alleles among
rs2305480-GG homozygotes, although this effect did
not reach significance in this sample (OR = 1.34, 95% CI
0.95, 1.88; P = 0.096) (Additional file 1: Fig. S14).
Associations between African‑specific variants and asthma
severity

To further generalize these results to asthma severity
and to adults, we examined available data on severity
for 63 African American asthmatic adults who have
participated in genetic studies in Chicago [45]. Because
we did not have sequence data for these individuals,
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Fig. 5 Clinical phenotype associations with the novel variants and haplotype 4. A Correlation plot of the seven asthma-associated quantitative
phenotypes in African American children from the URECA and APIC cohorts and their association with rs113282230 genotypes. B Bar plot showing
the frequency of the 5-SNP high-risk haplotype 4 by STEP classification categories (mild, moderate, and severe) [47] in African American adults from
Chicago. Severity categories and sample sizes are shown on the x-axis and the frequency of haplotype 4 is shown on the y-axis. Haplotype 4 was
used as a surrogate for the nine novel SNPs because neither whole-genome sequences nor imputed genotypes for these variants were available
for these individuals. C Bar plot of the frequencies of asthma severity categories in African American adults with asthma who carry at least one
rs2305480-G allele, stratified by the presence or absence of haplotype 4 (x-axis). None of these individuals were homozygous for haplotype 4

we used as a surrogate the 5-SNP haplotype and tested
for an association between the high-risk haplotype 4
and asthma severity, defined as mild, moderate, and
severe based on lung function and steroid use [47].
Consistent with the analysis of APIC and URECA children described above, the frequency of haplotype 4
increased with increasing asthma severity in African
American adults (ordinal logistic regression β=1.58,
95% CI 0.38, 2.79; p = 0.012) (Fig. 5B). To directly
test whether the presence of haplotype 4 adds to the
risk conferred by the rs2305480-G allele, we further
stratified the 59 adults who carried at least 1 copy of
rs2305480-G into two groups based on whether they
also carried 0 (n=41) or 1 (n=18) copies of haplotype 4
(none of the subjects carried two copies of haplotype 4).
We compared the number of subjects who were classified as mild, moderate, or severe within the two groups.
If haplotype 4 did not impact asthma severity beyond
the effects of the rs2305480-G allele, the distributions
by severity should be similar in the two groups. However, among adult asthmatics with at least one copy of
the rs2305480-G allele, there was a greater proportion
of severe asthma cases among those also carrying haplotype 4 compared to those not carrying haplotype 4
(ordinal logistic regression β = 1.68, 95% CI 0.42, 2.93;
p = 0.011; Fig. 5C, Additional file 1: Table S10). These
combined results support a role for the novel variants,
which are enriched on haplotype 4, in asthma severity
in both children and adults.

Discussion
Compared to children of European ancestry, African
American children have a higher prevalence of asthma
[48] that develops at a younger age [49, 50] and results in
lower lung function [51], poorer response to asthma therapies [52], and more emergency room visits and hospitalization for asthma [53]. Although social and behavioral
inequities clearly impact disparities in health outcomes
among these populations [54], genetic differences may
contribute as well. That is, among the many genetic variants whose frequencies differ among worldwide populations, some may contribute to observed disparities [55].
However, the focus of large GWAS in individuals primarily of European ancestry has limited our ability to
identify variants that are relevant to non-European populations [1, 2, 4]. In this study, we addressed this gap by
using whole-genome sequences to identify variants at the
17q12-q21 childhood-onset asthma locus that contribute
to asthma risk specifically in African American individuals. Our conclusions are based on multiple independent lines of evidence from complementary data sources,
which increase the confidence of our findings [56] and
underscore the importance of allelic heterogeneity at this
important locus, with different variants regulating the
expression of different genes. Overall, these results raise
the possibility that genotype-specific risks may be modified by genetic background.
Based on previous observations of reduced effects
of 17q12-q21 GWAS variants on asthma risk in
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African American children [9, 10, 17] and the significantly reduced LD in this region in African-ancestry
populations (reviewed in ref. [11]), we hypothesized
that additional variation on African-ancestry chromosomes at this locus modifies risk for childhood asthma.
Analyses of the haplotype structures at single-nucleotide
resolution in European American and African American
individuals identified a 26.3-kb critical region on a highrisk haplotype and led to the discovery of nine common
variants that are rare on European-ancestry haplotypes.
Our results suggested that the novel variants are associated with increased expression of GSDMA via long-range
chromatin interactions and are associated with a type 2
(T2) low asthma phenotype in African American children and asthma severity in African American adults.
The gasdermin family of proteins mediate pyroptosis,
a form of programmed necrotic cell death initiated in
response to intracellular pathogens that leads to activation of caspase-1 or caspase-4/5 and results in gasderminmediated pore formation in cell membranes and eventual
rupture and release of pro-inflammatory cytokines such
as IL-1β [57]. Expression and function of gasdermin B,
encoded by GSDMB, has been directly linked to genetic
variation at the core region of the 17q12-q21 locus and to
processes relevant to asthma [58]. Two SNPs that are in
near perfect LD, rs2305480 (Pro298Ser) and rs11078928
(c.662T→C), alter protein conformation and surface
charge [59] and expression of the full-length transcript
[18, 60], respectively. We and others have recently shown
that risk for asthma conferred by variation at the 17q12q21 locus was due to these SNPs, implicating GSDMB
function and/or expression in airway epithelial cells in
asthma pathogenesis [17, 18, 61].
Another gene in the gasdermin family, GSDMA, resides
outside of the core region at the proximal end of the
17q12-q21 locus, where LD (r2) between the lead GWAS
SNPs in the core region (i.e., rs2305480 or rs11078928)
with GSDMA SNPs is approximately 0.4 in European
Americans but ≤0.10 in African Americans (see Stein
et al. [11]). As a result, it has been difficult to determine whether the GWAS signal with SNPs in the distal
GSDMA region are independent signals for asthma risk
in European-ancestry populations, or merely a result of
their LD with the core region SNPs. In our studies of children in the CREW cohorts [17], considering the alleles
associated with asthma in Europeans as the effect alleles,
SNPs in GSDMA had estimated ORs >1 in the European
American sample but ORs <1 in the African American
sample (Fig. 1 in [17]). We attributed this finding to the
very different LD patterns between these populations but
did not have sufficient power to determine whether the
GSDMA SNPs were significantly associated with asthma
in the African American sample. However, those results
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are consistent with the data we report here. That is, the
common GSDMA alleles associated with reduced risk
of asthma in the CREW African American cohort were
associated with reduced GSDMA expression in lung tissue [14], in nearly all tissues in the Genotype-Tissue
Expression consortium [62], and in upper airway epithelial cells in our study (Additional file 1: Table S5). These
data combined with the results we report here provide
a link between GSDMA expression and asthma risk and
convergent evidence for increased expression of GSDMA
promoting asthma pathobiology.
Notably, the high-risk haplotype 4 includes variants
associated with increased expression of both GSDMB
(i.e., rs2305480 and rs113571956) and GSDMA (i.e.,
rs11382230 and rs113571956). The increased expression
of both gasdermin genes in individuals carrying haplotype 4 may account for the modifying effects of this
haplotype on asthma risk and severity. For example, in a
combined sample of African American children from two
cohorts (APIC and URECA), the rs113282230-T allele
was associated with reduced lung function, a marker of
asthma severity, lower blood neutrophil count, potentially reflecting rapid turnover due to increased trafficking to mucosal surfaces in response to epithelial signals,
and low total serum IgE, reflecting a T2-low asthma
phenotype [63]. In an independent sample of adults with
asthma, haplotype 4 was also associated with asthma
severity.
While our study provides evidence for African-specific
variants that modify the genetic risk attributed to the
17q12-q21 childhood-onset asthma locus by increasing
expression of GSDMA, there are limitations. First, the
novel SNPs occur exclusively on haplotypes with variants
associated with increased GSDMB expression. Therefore, we could not determine whether the novel alleles
by themselves contribute to asthma risk or whether
increased expression of GSDMA modifies risk only in the
presence of increased GSDMB expression. Future studies using gene editing approaches, creating isogenic cell
lines with combinations of genotypes in which the shared
and African-specific asthma risk variants can be decoupled, could help to differentiate these possibilities. Second, airway epithelial cell expression of GSDMA was too
low to determine whether the combined expression levels
of both genes were associated with greater risk or severity of asthma compared to expression levels of each gene
separately. Nonetheless, we demonstrated that haplotype
4 was associated with asthma in Black children in the
CREW cohort and asthma severity in Black adults. Using
phenotype and whole-genome sequence data in two African American cohorts, we further showed that the novel
variants were associated with markers of T2-low, severe
asthma in children. Finally, we focused our eQTL and
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chromatin studies in airway epithelial cells. The rationale for this choice was that these are sentinel cells in
the airway that respond to inhaled microbes, pollution,
and allergens and mediate their downstream effects on
asthma risk. In our earlier study [17], we showed that
expression of GSDMB in airway epithelial cells, but not
in peripheral blood cells, modulated the risk for childhood-onset asthma at the 17q12-q21 locus. However, we
cannot rule out the possibility that the novel variants regulate the expression of other genes in immune cells under
specific conditions that modify the features of asthma
severity observed in our study.

Conclusions
This study provides a strategy for identifying populationspecific disease-associated variants at GWAS loci that
were missed in previous studies. We suggest that other
loci with effect sizes that differ among global populations would be amenable to such an approach and potentially yield a wealth of functional variants that are missed
by current GWAS and fine-mapping approaches. The
abundance of whole-genome sequence data now available in worldwide populations will facilitate the discovery of such variants and provide a rich source of novel
therapeutic targets and a substrate for truly personalized
medicine.
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